VERQUVO-10MG-14 TABLET (Vericiguat 10 mg) Heart Failure Tablets
VERQUVO-10MG-14 TABLET contains Vericiguat 10 mg, a prescription soluble guanylate cyclase stimulator used to reduce the risk of cardiovascular death and heart failure hospitalization in eligible adults.
H1 (20–50 characters)
VERQUVO-10MG-14 TABLET
VERQUVO-10MG-14 TABLET (Vericiguat 10 mg): Comprehensive Guide and Benefits
Introduction to VERQUVO-10MG-14 TABLET (Vericiguat 10 mg)
VERQUVO-10MG-14 TABLET (Vericiguat 10 mg): A Soluble Guanylate Cyclase (sGC) Stimulator
VERQUVO-10MG-14 TABLET is a prescription-only cardiovascular medicine containing Vericiguat 10 mg. It belongs to the soluble guanylate cyclase (sGC) stimulator class and is indicated for adults with symptomatic chronic heart failure with reduced ejection fraction (HFrEF) following a recent worsening heart failure event requiring hospitalization or intravenous diuretic therapy. It is used in combination with standard guideline-directed heart failure treatment.
Vericiguat enhances the nitric oxide–soluble guanylate cyclase–cyclic GMP pathway, helping improve vascular function and supporting cardiovascular performance. Clinical studies have shown that it reduces the risk of cardiovascular death and heart failure hospitalization in appropriately selected patients. Treatment should be initiated and monitored by a qualified healthcare professional, with regular assessment of blood pressure, kidney function, and overall clinical status.
Key Benefits of VERQUVO-10MG-14 TABLET (Vericiguat 10 mg)
Helps reduce the risk of cardiovascular death in eligible patients with chronic heart failure.
Lowers the likelihood of hospitalization due to worsening heart failure.
Complements standard guideline-directed heart failure therapy.
Improves nitric oxide signaling involved in cardiovascular function.
Convenient once-daily oral treatment.
How VERQUVO-10MG-14 TABLET (Vericiguat 10 mg) Works
Vericiguat directly stimulates soluble guanylate cyclase (sGC) and increases its sensitivity to endogenous nitric oxide. This increases intracellular cyclic guanosine monophosphate (cGMP) production, promoting relaxation of vascular smooth muscle, improving endothelial function, and supporting cardiac performance. By restoring impaired nitric oxide signaling commonly observed in chronic heart failure, vericiguat helps reduce adverse cardiovascular outcomes when used alongside standard heart failure therapy.
Usage Instructions for VERQUVO-10MG-14 TABLET
Take exactly as prescribed by your healthcare provider.
Swallow the tablet once daily with food.
Take it at approximately the same time each day.
Attend regular follow-up visits to monitor blood pressure, kidney function, and heart failure status.
Do not stop or change the dose without consulting your healthcare provider.
Medicinal Advantages of VERQUVO-10MG-14 TABLET
Clinically proven to reduce heart failure hospitalization.
Helps lower the risk of cardiovascular death in eligible patients.
Novel mechanism targeting impaired nitric oxide signaling.
Convenient once-daily oral dosing.
Can be combined with other evidence-based heart failure therapies.
NOTE: VERQUVO-10MG-14 TABLET is a prescription-only medicine. It is contraindicated during pregnancy because it may cause fetal harm. Women of reproductive potential should undergo pregnancy testing before treatment and use effective contraception during therapy and for one month after discontinuation.
Off-Label Uses of VERQUVO-10MG-14 TABLET
Vericiguat is approved for specific patients with symptomatic chronic heart failure. Any use outside approved indications should be based on specialist clinical judgment.
Individualized management of selected heart failure patients.
Specialist-directed cardiovascular treatment strategies.
Research-supported use in carefully selected clinical circumstances.
Disclaimer: Off-label uses should only occur under physician supervision and may not be approved in all countries.
Expert Advice for Optimal Use
Take the medicine with food every day.
Continue all prescribed heart failure medications unless advised otherwise.
Monitor your blood pressure regularly.
Report dizziness, fainting, or worsening heart failure symptoms promptly.
Follow dietary and lifestyle recommendations for heart failure management.
Keep all scheduled cardiology appointments.
Precautions
Cardiovascular Health
Monitor blood pressure regularly, as symptomatic hypotension may occur. Continue regular follow-up with your cardiologist throughout treatment.
Liver & Kidney Function
Kidney and liver function should be evaluated before and during treatment. Patients with significant impairment may require closer monitoring.
Pregnancy & Breastfeeding
VERQUVO is contraindicated during pregnancy because of the risk of embryo-fetal toxicity. Women of childbearing potential should use effective contraception during treatment and for one month after the last dose. Breastfeeding is generally not recommended during treatment.
Drug Interactions
Do not use VERQUVO with other soluble guanylate cyclase stimulators such as riociguat. Concomitant use with PDE-5 inhibitors is generally not recommended because of the increased risk of hypotension. Always inform your healthcare provider about all medicines and supplements you are taking.
Existing Medical Conditions
Inform your healthcare provider if you have severe hypotension, kidney disease, liver disease, anemia, or other chronic cardiovascular conditions before starting therapy.
Storage Instructions
Store below 30°C or according to the package label.
Keep the tablets in their original blister pack.
Protect from excessive heat, moisture, and direct sunlight.
Keep out of the reach of children and pets.
Do not use after the expiry date.
Frequently Asked Questions (FAQs)
Q: What is VERQUVO-10MG-14 TABLET used for?
A: It is used to reduce the risk of cardiovascular death and hospitalization in eligible adults with symptomatic chronic heart failure with reduced ejection fraction.
Q: What is the active ingredient in VERQUVO-10MG-14 TABLET?
A: Each tablet contains Vericiguat 10 mg, a soluble guanylate cyclase (sGC) stimulator.
Q: Should VERQUVO-10MG-14 TABLET be taken with food?
A: Yes. It should be taken once daily with food to optimize absorption.
Q: Can I stop taking VERQUVO-10MG-14 TABLET if I feel better?
A: No. Continue taking the medicine unless your healthcare provider advises you to stop.
Q: Is VERQUVO-10MG-14 TABLET safe during pregnancy?
A: No. It is contraindicated during pregnancy because it may cause fetal harm.
Q: What are the common side effects?
A: The most commonly reported side effects include hypotension (low blood pressure) and anemia. Contact your healthcare provider if these become severe or persistent.
Q: Is VERQUVO-10MG-14 TABLET available without a prescription?
A: No. It is a prescription-only medicine and should be used under the supervision of a qualified healthcare professional.
Product Tags
VERQUVO-10MG-14 TABLET, Vericiguat 10 mg, Vericiguat Tablet, Soluble Guanylate Cyclase Stimulator, sGC Stimulator, Heart Failure Medicine, Chronic Heart Failure Treatment, HFrEF Therapy, Cardiovascular Medicine, Prescription Heart Failure Drug, Verquvo 10 mg, Heart Failure Hospitalization Prevention, Cardiovascular Death Risk Reduction, Once Daily Heart Failure Tablet, Cardiology Medication, Nitric Oxide Pathway, Guideline-Directed Heart Failure Therapy, Vericiguat Prescription, Oral Heart Failure Treatment, Heart Failure Tablets
